Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study. - Fricke JG; Westerbergh F; McDougall L; Favaretto C; Christ E; Nicolas GP; Geistlich S; Schmid DE; Borgna F; Fani M; Bernhardt P; van der Meulen NP; et al. (Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026)